Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients With Non-Myeloid Malignancies Receiving Chemotherapy

NCT00111137 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00111137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00111137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2003
Completion date
April 30, 2004
Enrollment
718 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, non-myeloid malignancies